RedHill Biopharma buys commercialization rights to Ferring’s Rebyota, Clenpiq for $12 million upfront
RDHL•RedHill acquires commercialization rights to Ferring GI products
RedHill Biopharma acquired exclusive commercialization rights to Ferring’s Rebyota and Clenpiq in a strategic GI portfolio shift.
- Upfront payment set at $12 million, with additional milestones and tiered royalties tied to net sales.
- Rebyota generated about $16.9 million in 2025 U.S. net sales; Clenpiq produced $20.6 million.
- The transaction was funded from an earlier $18 million Talicia divestment, leaving RedHill with a larger commercial GI business.
- The Rebyota license covers global commercialization; Clenpiq rights cover the U.S., with Ferring continuing to manufacture and supply Rebyota.
